Serina Therapeutics, Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Serina Therapeutics is in Stage 3, the topping phase, now in week 2 (since Oct 15, 2026). It closed at $1.76, 66.5% below its 52-week high and below its 200-day average, which is falling.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. More about the company

$1.76

-0.56% today

$44.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is SER early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S4 17w

S4 34w

S4 33w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 6w → S3 8w → S4 14w → S1 5w → S4 17w → S1 2w → S4 34w → S1 9w → S2 6w → S3 9w → S4 33w → S1 2w → S4 6w → S1 7w → S2 6w → S3 1w current

Total tracked: 166 weeks across 16 stage runs.

SER among Biotechnology411th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…411	SERSerina Therapeutics, Inc.	Stage 3 · wk 2	17	−19.6%

vs 52W High

-66.5%

$1.28 lo$5.26 hi

66.5% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-16.7%

200 DMA: $2.11 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.73x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-19.6%

-15.0%

-9.3%

YTD

-15.3%

-64.1%

Scan Membership

Breakout Watch

Latest: 2025-06-13

5 appearances in last 60 days. First seen: 2020-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 0.73x

2026-10-21S3

Wk 1 · Vol 0.54x

2026-10-20S3

Wk 1 · Vol 0.57x

2026-10-19S3

Wk 1 · Vol 0.30x

2026-10-16S3

Wk 1 · Vol 0.21x

2026-10-15S32→3

Wk 1 · Vol 0.36x

2026-10-14S2

Wk 6 · Vol 0.62x

2026-10-13S2

Wk 6 · Vol 0.35x

2026-10-12S2

Wk 6 · Vol 1.82x

2026-10-09S2

Wk 6 · Vol 0.31x

2026-10-08S2

Wk 5 · Vol 0.83x

2026-10-07S2

Wk 5 · Vol 0.18x

Moving averages & range

50 DMA

$2.27

200 DMA

$2.11

52W High

$5.26

52W Low

$1.28

5D Low

$1.65

Resistance levels (recent highs)

20d High

$2.09

60d High

$2.87

120d High

$2.87

250d High

$5.26

Next resistance

+18.7%

to 20d High

ROE

-207.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.4

Serina Therapeutics: quick answers

What stage is Serina Therapeutics in?

As of Oct 22, 2026, Serina Therapeutics (SER) is in Stage 3, the topping phase. It entered Stage 3 on Oct 15, 2026 and is in week 2. What the four stages mean

Is Serina Therapeutics in an uptrend?

Its uptrend has stalled. Serina Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 16.7% below its 200-day average, which is falling.

How far is Serina Therapeutics from its 52-week high?

Serina Therapeutics closed at $1.76 on Oct 22, 2026, 66.5% below its 52-week high of $5.26. Its 52-week low is $1.28.

How has Serina Therapeutics performed over the past year?

As of Oct 22, 2026, Serina Therapeutics is down 64.1% over the past year and down 15.3% so far in 2026.

Which sector and industry is Serina Therapeutics in?

Serina Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.